The 3rd Princess Margaret Hospital Conference on New Developments in Cancer Management

Venue: Marriott Eaton Centre

Location: Toronto, Ontario, Canada

Event Date/Time: Sep 10, 2003 End Date/Time: Sep 13, 2003
Registration Date: Sep 03, 2003
Early Registration Date: Jul 11, 2003
Report as Spam

Description

This program is designed for practicing oncologists and other health care personnel with a special interest in Oncology. The purpose of the meeting is to update attendees on standard cancer therapies, new experimental programs and advances in supportive care, which they may consider to apply in the treatment of their cancer patients in their own institution or practice setting. Most of the information will be presented by distinguished faculty from Princess Margaret Hospital, one of the largest multidisciplinary cancer centers in North America, as well as a pioneer in basic research and development of new cancer treatments. In addition, as at previous meetings, the Organizing Committee has invited a select few guest-speakers from other world renowned cancer centers in North America to present their data and their views on certain topics.

The program will meet the requirements of the Royal College of Physicians and Surgeons of Canada to provide CME credits, as they are now required by all Canadian specialists. This activity has also been planned and implemented in accordance with the Essential Areas and Policies of the U.S. Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of Imedex®, Inc.

If you are not familiar with Toronto, participation at this meeting will also allow you to visit one of the nicest and safest cities in North America at a time when the weather is excellent and early signs of autumn will be upon us. A bonus is that the prestigious Toronto International Film Festival will be ongoing at the same time along with the good selection of live theatre and music that is always present in Toronto. Excellent museums and other interesting sites are to be found throughout the city and Toronto is less than a two-hour drive from Niagara Falls, one of the natural wonders of the world. Because of the city’s multicultural makeup, the choice of good restaurants of every type and price range is enormous, and the food is among the best in the world. We hope you will make the time to partake in all that the city has to offer while updating yourself in oncology.

Scientific Program
The 3rd Princess Margaret Hospital Conference on New Developments in Cancer Management
September 10-13, 2003
Toronto, Canada

Thursday, September 11, 2003

9:00 am Welcome and introduction

9:10 am Molecular Targeting: Can The Medicine of Today Become The Magic of Tomorrow
Tak Mak, PhD
10:10 am Break

Session I: Gynecological cancers
10:30 am Carcinoma of the cervix: Introduction and overview
Anthony W. Fyles, MD
10:40 am Controversies in the surgical management of cervix carcinoma
Stephane LaFramboise, MD
10:55 am Chemoradiation for carcinoma of the cervix
Gillian Thomas, MD
11:10 am Recent advances in radiation therapy for carcinoma of the cervix
Michael Milosevic, MD
11:25 am Systemic therapy for cervix carcinoma
Amit M. Oza, MD
11:40 am Q&A/Discussion
11:55 am Lunch Symposium
Lunch supported by Merck Frosst

Session II: Hematopoietic malignancies
1:30 pm Approaches to plasma cell dyscrasias
Donna Reece, MD
1:50 pm What’s new in the management of large cell lymphoma?
Michael Crump, MD
2:10 pm Changes in assessment and therapy of follicular lymphomas
Ian Quirt, MD
2:30 pm Which patients with Hodgkin’s disease should receive radiotherapy?
Mary Gospodarowicz, MD
2:50 pm Q&A/Discussion
3:05 pm Break

Session IIIA: Sarcoma (in parallel with IIIB)
3:20 pm C-kit mutations in GIST and the use of imatinib
Martin Blackstein, MD, PhD
3:40 pm Surgical management and local control of sarcomas of the extremities
Robert Bell, MD
4:00 pm The role of radiotherapy in soft tissue sarcoma
Brian O’Sullivan, MD
4:20 pm The role of chemotherapy in soft tissue sarcoma
Robert Maki, MD
4:40 pm Q&A/Discussion

Session IIIB: Nursing session (parallel with IIIA)
3:20 pm Outpatient febrile neutropenia treatment in the leukemia patient population
Cindy Murray, RN, MN
3:45 pm Breast cancer survivorship program design and implementation
Val Ali, RN, BA
4:10 pm New developments in radiation oncology nursing
Maurene McQuestion, RN, BA
4:35 pm Q&A/Discussion

Session IV: Genitourinary cancer
5:00 pm Is there a role for retroperitoneal lymphadenectomy in the management of NSGCT? Michael Jewett, MD
5:20 pm Prostate cancer: What to do when surgery fails?
Charles Catton, MD
5:40 pm Prostate cancer: What to do when radiation fails?
John Trachtenberg, MD
6:00 pm Prostate cancer: What to do when hormones fail?
Jennifer Knox, MD
6:20 pm Q&A/Discussion


Friday, September 12, 2003

Session V: Thoracic cancer
8:30 am Is there a role for surgery in NSCLC patients with N2 disease?
Kathy S. Albain, MD
8:50 am Which first-line chemotherapy combinations are recommended for advanced NSCLC
in 2003?
Frances A. Shepherd, MD
9:10 am Chemotherapy for mesothelioma
Natasha Leighl, MD
9:30 am Chemoradiation with new drugs and cisplatin combinations: Radiosensitization issues
Andrea Bezjak, MD
9:50 am Q&A/Discussion
10:05 am Break

Session VI: Breast cancer
10:25 am Management of local recurrence
David R. McCready, MD
10:45 am Should chemo plus hormone therapy be standard for all post menopausal women with
primary breast cancer?
Kathy S. Albain, MD
11:10 am Ovarian ablation in adjuvant therapy of breast cancer
Kathleen Pritchard, MD
11:35 am Q&A/Discussion
11:50 am Lunch Symposium
Lunch supported by AstraZeneca

Session VII: Supportive care
1:30 pm The role of stereotactic radio-surgery in the management of patients with brain metastases
Normand Laperriere, MD
1:50 pm Should prostate cancer patients receive bisphosphonates?
David Warr, MD
2:10 pm Intraspinal analgesia: What every oncologist should know
Vincent Chan, MD
2:30 pm What are the risks of giving chemotherapy in patients with previous hepatitis B or C?
Morris Sherman, PhD
2:50 pm Q&A/Discussion

3:05 pm Break

3:25 pm Cases
Presentation and discussion of challenging cases of cancers discussed above

4:30 pm Adjourn


Saturday, September 21, 2002


Session VIII: Gastrointestinal cancers

8:30 am Pre- vs. postoperative (chemo)radiotherapy for rectal cancer
James Brierley, MD

8:55 am Total mesorectal excision for rectal cancer
Marko Simunovic, MD

9:20 am Advances in adjuvant chemotherapy for colorectal cancer
Charles Erlichman, MD

9:45 am Q&A/Discussion

10:00 am Break


Session IX: New drugs in cancer treatment

10:20 am Interesting molecular-targeted agents: The Mayo Clinic experience
Charles Erlichman, MD

10:40 am Interesting molecular-targeted agents: The PMH experience
Amit M. Oza, MD

11:00 am Identification of drug targets
Mark Bray, MD

11:20 am How (and how not to) develop a drug: Hindsight from a drug developer
Lillian Siu, MD

11:40 am Q&A/Discussion

12:05 pm Lunch break

Session X: Hematological cancers

1:30 pm Diagnosis and management of leukemia: An interactive session with vignettes
Mark Minden, MD, PhD

1:50 pm Additional presentations

3:00 pm Conclusion and farewell

3:10 pm Adjourn

Venue

525 Bay Street
Toronto
Ontario
Canada
MORE INFO ON THIS VENUE

Additional Information

Register online at www.imedex.com, Tel.: +1 770-751-7332, fax: +1 770-751-7334

Types